title: Drugs Used in Paediatric Bone and Calcium Disorders.
abstract: Calcium and bone disorders in children and adolescents are treated with a wide variety of drugs. Several of these drugs have been used for many years on the basis of accepted practice, without being subjected to rigorous trials. Bisphosphonates are the mainstay treatment for children with osteoporosis, but newer, more potent compounds such as zoledronate and risedronate have begun to replace the older-generation bisphosphonates. Hypocalcaemia is managed with calcium and vitamin D and its metabolites. In difficult cases that are secondary to hypoparathyroidism, subcutaneous injections or infusions of parathyroid hormone have been used. Multiple daily phosphate supplements and calcitriol are the standard treatment for hypophosphataemic rickets, but trials of an anti-fibroblast growth factor 23 antibody appear promising, and the results are eagerly awaited. Many new medications are undergoing clinical trials and are starting to emerge as viable treatment options for children. Some of these drugs target specific diseases, such as recombinant alkaline phosphatase for hypophosphatasia and a C-type natriuretic peptide analogue for achondroplasia. Other drugs, such as denosumab and odanacatib, have been used successfully in the adult population, and the appropriate use of these drugs in children is now being evaluated.
authors.affiliation: Great Ormond Street Hospital, London, UK.
authors.forename: Moira S
authors.initials: MS
authors.lastname: Cheung
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy; D001842:Bone and Bones / Q000378:metabolism; D002116:Calcitonin / Q000627:therapeutic use; D002117:Calcitriol / Q000627:therapeutic use; D002118:Calcium / Q000627:therapeutic use*; D002648:Child; D000069448:Denosumab / Q000627:therapeutic use; D004164:Diphosphonates / Q000627:therapeutic use*; D004232:Diuretics / Q000627:therapeutic use; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy*; D054559:Hyperphosphatemia / Q000188:drug therapy; D006996:Hypocalcemia / Q000188:drug therapy*; D017674:Hypophosphatemia / Q000188:drug therapy; D007093:Imidazoles / Q000627:therapeutic use; D010024:Osteoporosis / Q000188:drug therapy*; D010281:Parathyroid Hormone; D010710:Phosphates / Q000627:therapeutic use; D000068296:Risedronic Acid / Q000627:therapeutic use; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use; D014807:Vitamin D / Q000627:therapeutic use; D000077211:Zoledronic Acid
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D004232:Diuretics; D005938:Glucocorticoids; D007093:Imidazoles; D010281:Parathyroid Hormone; D010710:Phosphates; D049994:Sodium Potassium Chloride Symporter Inhibitors; D014807:Vitamin D; D000069448:Denosumab; D000077211:Zoledronic Acid; D002116:Calcitonin; D002117:Calcitriol; D000068296:Risedronic Acid; D000086:Acetazolamide; D002118:Calcium